Video

Dr. Fukuoka on Dosage for Regorafenib/Nivolumab Combo in Gastric Cancer and CRC

Author(s):

Shota Fukuoka, MD

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib (Stivarga) plus nivolumab (Opdivo) in patients with advanced gastric cancer or colorectal cancer (CRC).

The first cohort was used to determine the recommended dose, according to Kukuoka. Previously treated patients with advanced gastric cancer or CRC were given 80 to 160 mg of regorafenib daily for 21 days on and 7 days off with intravenous nivolumab at 3 mg/kg every 2 weeks. Researchers wanted to determine the dose-limiting toxicity (DLT) as the primary endpoint.

The dose-expansion cohort of patients received 80 mg of regorafenib plus nivolumab. The combination had a manageable safety profiles and encouraging antitumor activity in patients with gastric cancer and CRC. The objective response rate was 40% for all patients, 44% for patients with gastric cancer, and 36% for patients with CRC. The median progression-free survival was 6.3 months. Fukuoka believes these results warrant further research.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Shubham Pant, MD, MBBS
July 24th 2024

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Richard Kim, MD
July 19th 2024

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tanios S. Bekaii-Saab, MD
July 18th 2024

Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study

RMC-6236 in Previously Treated PDAC
July 16th 2024

RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC